Evidence map›Paper›PMID 31162140›Full record

ArticleJCI insight2019

Racial differences in the association of NT-proBNP with risk of incident heart failure in REGARDS.

Nirav Patel, Mary Cushman, Orlando M Gutiérrez, George Howard, Monika M Safford, Paul Muntner, Raegan W Durant, Sumanth D Prabhu, Garima Arora, Emily B Levitan and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04055428 (The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04055428 phase2recruitingnot on this mapstarted 2020, after this paper: background citation

The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals (NAUTICAL)

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2020 to 2027Enrolled200ConditionsDiabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic DiseaseArmsSacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test, Standardized Meals, Exercise capacity VO2 maximum determination
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Nirav PatelDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Mary CushmanDivision of Hematology and Oncology, Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA.
Orlando M GutiérrezDivision of Nephrology, Department of Medicine.
George HowardDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Monika M SaffordDivision of General Internal Medicine, Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
Paul MuntnerDepartment of Epidemiology, and.
Raegan W DurantDivision of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Sumanth D PrabhuDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Garima AroraDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Emily B LevitanDepartment of Epidemiology, and.
Pankaj AroraDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
University of Alabama at Birmingham · USCornell University · USUniversity of Vermont · US

Funding

VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
REGARDS - MI StudyR01HL080477 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEVITAN, EMILY B, SAFFORD, MONIKA M · 2006 to 2020
$11.6M
Basic and Translational Science in Heart FailureT32HL129948 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YOUNG, MARTIN E · 2017 to 2021
$1.4M
Race, Natriuretic Peptides and Physiological PerturbationsK23HL146887 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ARORA, PANKAJ · 2019 to 2023
$969k
NHLBI NIH HHS K23 HL146887NHLBI NIH HHS R01 HL080477NHLBI NIH HHS T32 HL129948NINDS NIH HHS U01 NS041588
6 · The paper itself

Abstract

backgroundBlack individuals have lower natriuretic peptide levels and greater risk of heart failure (HF) than white individuals. Higher N-terminal-pro-B-type natriuretic peptide (NT-proBNP) is associated with increased risk of incident HF, but little information is available in black individuals. We examined race-specific differences in 1) the association of NT-proBNP with incident HF and 2) the predictive ability of NT-proBNP for incident HF across body mass index (BMI) and estimated glomerular filtration rate (eGFR) categories.

methodsIn a prospective case-cohort study, baseline NT-proBNP was measured among 687 participants with incident HF and 2,923 (weighted 20,075) non-case randomly selected participants. Multivariable Cox proportional hazard modeling was used to assess the objectives of our study. Global Wald Chi-square score estimated from multivariable Cox models was used to assess predictive ability of NT-proBNP across BMI and eGFR categories.

resultsIn the multivariable model, a doubling of NT-proBNP concentration was associated with greater risk of incident HF among white individuals [hazard ratio (HR): 1.73; 95% CI: 1.55-1.94] than black individuals (HR: 1.51; 95% CI: 1.34-1.70); Pinteraction by race = 0.024. Higher NT-proBNP was the strongest predictor of incident HF across all BMI and eGFR categories among white individuals. By contrast, among black individuals with obesity (BMI ≥ 30 kg/m2) or eGFR < 60 mL/min/1.73 m2, the predictive ability of NT-proBNP for incident HF was attenuated.

conclusionsThe magnitude of the association of higher NT-proBNP with incident HF risk was greater among white individuals than black individuals. The diminished ability of NT-proBNP to predict the risk of HF in black population with obesity or impaired kidney function highlights the need of further investigations.

Indexed as

AgedBody Mass IndexFemaleGlomerular Filtration RateHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainObesityPeptide FragmentsProspective StudiesRisk AssessmentRisk FactorsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)CardiologyEpidemiologyHeart failure

Identifiers

PMID31162140
PMCPMC6629159
OpenAlexW2948387046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.